Navarra – December 2022 – Medibiofarma S.L., a clinical-stage biotechnology company developing a portfolio of new therapies for the treatment of cancer and non-cancer diseases announced the first subject dosed in the Phase I clinical trial of MBF-362 in cancer patients with solid tumours.

MBF-362, a salt form of previous development candidate, MBF-251, has successfully completed pre-clinical development. The objectives of the current phase I trial are to determine the safety, tolerability and pharmacokinetic profile of MBF-362 during a dose escalation trial, and to determine the dose limiting toxicities (DLT), maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of MBF-362. This single-centre trial will be carried out at the Catalan Institute of Oncology (ICO), Barcelona.

With the start of this trial, Medibiofarma has successfully brought its three pre-clinical lead compounds into clinical trials.